(Q35621713)

9 August 2017

1 reference

title

Treatment of HBeAg-negative chronic hepatitis B with interferon or pegylated interferon (English)

1 reference

9 August 2017

1 reference

1 reference

1 reference

Maurizia Rossana Brunetto

1

0 references

author name string

Filippo Oliveri

2

1 reference

9 August 2017

Piero Colombatto

3

1 reference

9 August 2017

Barbara Coco

4

1 reference

9 August 2017

Pietro Ciccorossi

5

1 reference

9 August 2017

Ferruccio Bonino

6

1 reference

9 August 2017

language of work or name

1 reference

1 January 2003

1 reference

9 August 2017

published in

Journal of Hepatology

1 reference

9 August 2017

volume

39 Suppl 1

1 reference

9 August 2017

page(s)

S164-7

1 reference

Hepatitis B virus DNA in the sera of HBsAg carriers: a marker of active hepatitis B virus replication in the liver.

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900329-5

7 January 2021

Analysis of liver disease, nuclear HBcAg, viral replication, and hepatitis B virus DNA in liver and serum of HBeAg Vs. anti-HBe positive carriers of hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900329-5

7 January 2021

Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900329-5

7 January 2021

Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900329-5

7 January 2021

Management of hepatitis B: 2000--summary of a workshop

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900329-5

7 January 2021

Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900329-5

7 January 2021

Interferon alpha therapy in HBeAg-negative chronic hepatitis B: new data in support of long-term efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900329-5

7 January 2021

Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900329-5

7 January 2021

Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900329-5

7 January 2021

Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900329-5

7 January 2021

A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900329-5

7 January 2021

A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900329-5

7 January 2021

Genetic heterogeneity in the precore region of hepatitis B virus in hepatitis B e antigen-negative chronic hepatitis B patients: spontaneous seroconversion and interferon-induced seroconversion

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900329-5

7 January 2021

Low-dose recombinant interferon therapy in anti-HBe-positive chronic hepatitis B in Asian Indians

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900329-5

7 January 2021

Long-term evaluation of recombinant interferon alpha2b in the treatment of patients with hepatitis B e antigen-negative chronic hepatitis B in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900329-5

7 January 2021

The treatment of chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900329-5

7 January 2021

Long-term remission of chronic hepatitis B after alpha-interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900329-5

7 January 2021

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900329-5

7 January 2021

Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900329-5

7 January 2021

Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900329-5

7 January 2021

The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900329-5

7 January 2021

Interferon treatment in hepatitis B surface antigen-positive hepatitis B e antibody-positive chronic hepatitis B: role of hepatitis B core antibody IgM titre in patient selection and treatment monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900329-5

7 January 2021

10.1016/S0168-8278(03)00329-5

Identifiers

DOI

1 reference

9 August 2017

1 reference